ROEDER DOUGLAS A

SEC source: 0001209191-20-047750 · doc4a.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,077

F1 · shares: Represents a restricted stock unit ("RSU") grant. The RSUs vest in full on the earlier of the one year anniversary of the date of grant or the next annual stockholders meeting, subject to the reporting person's continuous service through such vesting date.

F2 · shares: This Form 4 amendment is being filed to reflect the correct vesting terms of the RSU grant.

F3 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001438133-20-000080 · wf-form4_159079987497213.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,892

Underlying: Common Stock · 1,892 shares

Expires not disclosed

F1 · security: Awarded on May 27, 2020 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F3 · derivative.exercise_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan.

F3 · derivative.expiration_date: Shares will vest on the one year anniversary of the grant date, subject to the terms of the 2013 Plan.

SEC source: 0000899243-19-022590 · doc4.xml · nonDerivative · entry 6

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,670

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F4 · price: This transaction was executed in multiple trades at prices ranging from $71.00 to $71.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-022590 · doc4.xml · nonDerivative · entry 5

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 990,330

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F4 · price: This transaction was executed in multiple trades at prices ranging from $71.00 to $71.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-022590 · doc4.xml · nonDerivative · entry 4

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,832

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F3 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-022590 · doc4.xml · nonDerivative · entry 3

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,006,924

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F3 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-022590 · doc4.xml · nonDerivative · entry 2

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 11,460

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-022590 · doc4.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,173,628

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F5 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-021162 · doc4.xml · nonDerivative · entry 2

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 12,651

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.105. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-021162 · doc4.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,295,646

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.105. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-019620 · doc4.xml · nonDerivative · entry 2

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 12,743

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-019620 · doc4.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,305,025

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001209191-19-038308 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,732

Underlying: Common Stock · 3,732 shares

Expires not disclosed

F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.

F2 · derivative.exercise_date: All shares subject to the option will vest in 12 equal monthly installments commencing one month following the date of grant.

F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant.

SEC source: 0000899243-19-017205 · doc4.xml · nonDerivative · entry 2

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 12,872

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F4 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000899243-19-017205 · doc4.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,318,243

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2019.

F2 · price: This transaction was executed in multiple trades at prices ranging from $70.00 to $70.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F3 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001209191-19-034083 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,930

Underlying: Common Stock · 86,930 shares

Expires 2029-05-29

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the NYSE American on the date of grant, May 30, 2019.

F2 · shares: This grant was made as compensation for the reporting person's service on the Issuer's board of directors. Under the Issuer's non-employee director compensation policy, each non-employee director who continues to serve as a member of the Issuer's board of directors is eligible to receive an annual stock option grant following each annual meeting of the Issuer's stockholders with a Black Scholes option value of $106,500.

F3 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of the one year anniversary of the date of grant or the next annual stockholders meeting, subject to the reporting person's continuous service (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through such vesting date.

SEC source: 0001209191-18-059320 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.

F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months.

F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant.

SEC source: 0001209191-18-038148 · doc4.xml · nonDerivative · entry 6

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 95,221

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $4.16, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 6 to this Form 4.

F4 · ownership.nature: The reported securities are directly owned by Delphi Bioinvestments VIII, L.P. ("DBI VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DBI VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DBI VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-038148 · doc4.xml · nonDerivative · entry 5

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 9,751,725

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $4.16, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 6 to this Form 4.

F3 · ownership.nature: The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DV VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DV VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-038148 · doc4.xml · nonDerivative · entry 4

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 101,131

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.08, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.

F4 · ownership.nature: The reported securities are directly owned by Delphi Bioinvestments VIII, L.P. ("DBI VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DBI VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DBI VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-038148 · doc4.xml · nonDerivative · entry 3

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 10,357,080

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.08, inclusive. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.

F3 · ownership.nature: The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DV VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DV VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-038148 · doc4.xml · nonDerivative · entry 2

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 102,632

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.11, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.

F4 · ownership.nature: The reported securities are directly owned by Delphi Bioinvestments VIII, L.P. ("DBI VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DBI VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DBI VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-038148 · doc4.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 10,510,803

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.11, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.

F3 · ownership.nature: The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DV VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DV VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-037591 · doc4.xml · nonDerivative · entry 4

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 104,700

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.79 to $3.98, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.

F4 · ownership.nature: The reported securities are directly owned by Delphi Bioinvestments VIII, L.P. ("DBI VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DBI VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DBI VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-037591 · doc4.xml · nonDerivative · entry 3

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 10,722,635

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.79 to $3.98, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 5 to this Form 4.

F3 · ownership.nature: The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DV VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DV VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-037591 · doc4.xml · nonDerivative · entry 2

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 107,236

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.79 to $3.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.

F4 · ownership.nature: The reported securities are directly owned by Delphi Bioinvestments VIII, L.P. ("DBI VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DBI VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DBI VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-037591 · doc4.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 10,982,325

F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 19, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.79 to $3.96, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.

F3 · ownership.nature: The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), the general partner of DV VIII, may be deemed to have sole dispositive and voting power over the securities directly owned by DV VIII. James J. Bochnowski, David L. Douglass, Deepika R. Pakianathan and Douglas A. Roeder are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim the existence of a "group" and disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-18-034687 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,847

Underlying: Common Stock · 50,847 shares

Expires 2028-05-29

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the NYSE American on the date of grant, May 30, 2018.

F2 · shares: This grant was made as compensation for the reporting person's service on the Issuer's board of directors. Under the Issuer's non-employee director compensation policy, each non-employee director who continues to serve as a member of the Issuer's board of directors is eligible to receive an annual stock option grant following each annual meeting of the Issuer's stockholders. The number of shares underlying the option is equal to a Black Scholes option value of $106,500.

F3 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of the one year anniversary of the date of grant or the next annual stockholders meeting, subject to the reporting person's continuous service (as defined in the Issuer's 2015 Equity Incentive Plan, as amended) through such vesting date.

SEC source: 0001209191-18-009618 · doc4.xml · nonDerivative · entry 2

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 13,217

F1 · balance_after: The amount of securities beneficially owned following the reported transactions reflects the 10 for 1 reverse stock split of the Issuer's issued and outstanding common stock which was effective on October 9, 2017.

F3 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi BioInvestments VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi BioInvestments VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi BioInvestments VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001209191-18-009618 · doc4.xml · nonDerivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,353,586

F1 · balance_after: The amount of securities beneficially owned following the reported transactions reflects the 10 for 1 reverse stock split of the Issuer's issued and outstanding common stock which was effective on October 9, 2017.

F2 · ownership.nature: The Reporting Person is a managing member of Delphi Management Partners VIII, L.L.C. ("DMP"), the general partner of Delphi Ventures VIII, L.P. As a managing member of DMP, the Reporting Person shares voting and investment power over the securities held by Delphi Ventures VIII, L.P. and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities held by Delphi Ventures VIII, L.P., except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001209191-17-064038 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,300

Underlying: Common Stock · 5,300 shares

Expires not disclosed

F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan.

F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over twelve (12) months.

F3 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant.

SEC source: 0001209191-17-061668 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700

Underlying: Common Stock · 1,700 shares

Expires not disclosed

F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.

F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months.

F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant.

SEC source: 0001209191-17-035928 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,817

Underlying: Common Stock · 128,817 shares

Expires 2027-05-23

F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the NYSE-MKT on the date of grant, May 24, 2017.

F2 · shares: This grant was made as compensation for the reporting person's service on the Issuer's board of directors. Under the Issuer's non-employee director compensation policy, each non-employee director who continues to serve as a member of the Issuer's board of directors is eligible to receive an annual stock option grant following each annual meeting of the Issuer's stockholders. The number of shares underlying the option is equal to a Black Scholes option value of $106,500.

F3 · derivative.exercise_date: The shares underlying the option will vest in full on the one year anniversary of the date of grant, subject to the reporting person's continuous service through the vesting date.

SEC source: 0001209191-16-150724 · doc4.xml · derivative · entry 1

ROEDER DOUGLAS A · CIK 0001270735 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 17,000 shares

Expires not disclosed

F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.

F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months.

F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant.